Related Experiment Video
Updated: Aug 5, 2026
06:00
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Selected Thieno[2,3-d] Pyrimidine Derivatives Target Breast Cancer Cell Proliferation and Membrane Organization
Aleksandrina Nesheva1, Ivan Iliev2, Anelia Mavrova3
1Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Bl. 21, 1113 Sofia, Bulgaria.
Molecules (Basel, Switzerland)
|July 28, 2026
Summary
Novel thieno[2,3-d]pyrimidine hybrids show promise as breast cancer treatments. These compounds effectively reduce cancer cell proliferation and migration, offering new therapeutic avenues.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- Breast cancer is a major global health concern, necessitating the development of new, effective therapies.
- Existing treatments face challenges with efficacy and selectivity, driving research into novel drug candidates.
Purpose of the Study:
- To evaluate the anticancer potential of thieno[2,3-d]pyrimidine-based hybrids against breast cancer cells.
- To investigate the effects of these compounds on cell viability, migration, and cell cycle progression.
Main Methods:
- Synthesized and tested thieno[2,3-d]pyrimidine derivatives in breast cancer cell models.
- Assessed effects on cell viability, colony formation, migration, cell cycle, and plasma membrane organization.
Main Results:
- Several derivatives demonstrated significant concentration-dependent antiproliferative and anti-migratory effects.
- Compounds 1, 5, and 6 showed favorable anticancer activity and selectivity.
- Compound 2 notably impacted plasma membrane organization and cell migration.
Conclusions:
- Thieno[2,3-d]pyrimidine hybrids represent promising lead compounds for breast cancer drug development.
- These agents target both tumor cell proliferation and plasma membrane integrity.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...